IL310865A - Antibodies against EDB and antibody-drug conjugates - Google Patents

Antibodies against EDB and antibody-drug conjugates

Info

Publication number
IL310865A
IL310865A IL310865A IL31086524A IL310865A IL 310865 A IL310865 A IL 310865A IL 310865 A IL310865 A IL 310865A IL 31086524 A IL31086524 A IL 31086524A IL 310865 A IL310865 A IL 310865A
Authority
IL
Israel
Prior art keywords
antibody
edb
seq
heavy chain
drug
Prior art date
Application number
IL310865A
Other languages
English (en)
Hebrew (he)
Inventor
Subramanyam Chakrapani
Michael May Chad
Therese Hooper Andrea
Ann Marquette Kimberly
Gerber Hans-Peter
Original Assignee
Pfizer
Subramanyam Chakrapani
Michael May Chad
Therese Hooper Andrea
Ann Marquette Kimberly
Hans Peter Gerber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Subramanyam Chakrapani, Michael May Chad, Therese Hooper Andrea, Ann Marquette Kimberly, Hans Peter Gerber filed Critical Pfizer
Publication of IL310865A publication Critical patent/IL310865A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL310865A 2016-10-17 2017-10-03 Antibodies against EDB and antibody-drug conjugates IL310865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409081P 2016-10-17 2016-10-17
PCT/IB2017/056093 WO2018073680A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Publications (1)

Publication Number Publication Date
IL310865A true IL310865A (en) 2024-04-01

Family

ID=60117722

Family Applications (2)

Application Number Title Priority Date Filing Date
IL310865A IL310865A (en) 2016-10-17 2017-10-03 Antibodies against EDB and antibody-drug conjugates
IL266112A IL266112B2 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL266112A IL266112B2 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Country Status (22)

Country Link
US (5) US20190269791A1 (enExample)
EP (3) EP3525828B1 (enExample)
JP (4) JP7039577B2 (enExample)
KR (1) KR102338660B1 (enExample)
CN (2) CN116251196A (enExample)
AU (3) AU2017344440B2 (enExample)
CA (1) CA3040423A1 (enExample)
DK (1) DK3525828T3 (enExample)
ES (1) ES3007557T3 (enExample)
FI (1) FI3525828T3 (enExample)
HR (1) HRP20250056T1 (enExample)
HU (1) HUE070615T2 (enExample)
IL (2) IL310865A (enExample)
LT (1) LT3525828T (enExample)
MX (2) MX2019004434A (enExample)
PL (1) PL3525828T3 (enExample)
PT (1) PT3525828T (enExample)
RS (1) RS66524B1 (enExample)
RU (1) RU2758632C2 (enExample)
SG (1) SG11201903400WA (enExample)
SI (1) SI3525828T1 (enExample)
WO (1) WO2018073680A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2020123425A2 (en) * 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
EP4340944A4 (en) * 2021-05-20 2026-04-01 Univ Case Western Reserve Specific Peptide and Drug Conjugates of Fibronectin Isotypes for Cancer Therapy
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
EP4716555A1 (en) * 2023-07-10 2026-04-01 Wuxi Xdc Singapore Private Limited Antibody-drug conjugates and production thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2002348477A1 (en) 2001-05-01 2002-12-23 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
PL369371A1 (en) * 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
ES2337566T3 (es) 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
KR20050026033A (ko) * 2002-07-31 2005-03-14 쉐링 악티엔게젤샤프트 신규 효과기 접합체, 그의 제조 방법 및 그의 약학적 용도
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
MX2007013875A (es) * 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
RU2467015C2 (ru) 2005-10-05 2012-11-20 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Белки шелка
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
JP2009535372A (ja) * 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
TWI412367B (zh) * 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
EA017995B1 (ru) 2007-07-25 2013-04-30 Филоджен С.П.А. Антиген, связанный с вариантами рака легкого и лимфомами
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
PL3912643T3 (pl) * 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
EP3842074A1 (en) 2010-09-29 2021-06-30 Philogen S.p.A. Protein-drug conjugates
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EA201591465A1 (ru) * 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
EP2988784A1 (en) * 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
SG11201605437YA (en) * 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
KR20190072663A (ko) * 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
TWI812873B (zh) * 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates

Also Published As

Publication number Publication date
EP3525828A1 (en) 2019-08-21
AU2017344440B2 (en) 2020-07-30
US20240261423A1 (en) 2024-08-08
JP2023184697A (ja) 2023-12-28
JP2019534706A (ja) 2019-12-05
RS66524B1 (sr) 2025-03-31
FI3525828T3 (fi) 2025-01-27
HUE070615T2 (hu) 2025-06-28
JP2025175010A (ja) 2025-11-28
CN110087691B (zh) 2023-02-03
SI3525828T1 (sl) 2025-04-30
US12636377B2 (en) 2026-05-26
JP7039577B2 (ja) 2022-03-22
LT3525828T (lt) 2025-02-25
WO2018073680A1 (en) 2018-04-26
BR112019007760A2 (pt) 2019-09-03
IL266112B1 (en) 2024-03-01
JP2022016581A (ja) 2022-01-21
RU2758632C2 (ru) 2021-11-01
DK3525828T3 (da) 2025-02-17
PL3525828T3 (pl) 2025-03-31
IL266112A (en) 2019-06-30
EP3525828B1 (en) 2024-12-25
US20240181071A1 (en) 2024-06-06
US12653901B2 (en) 2026-06-16
EP4617283A2 (en) 2025-09-17
IL266112B2 (en) 2024-07-01
RU2019111303A3 (enExample) 2020-11-17
SG11201903400WA (en) 2019-05-30
MX2019004434A (es) 2019-09-26
ES3007557T3 (en) 2025-03-20
HRP20250056T1 (hr) 2025-04-11
US20230241235A1 (en) 2023-08-03
PT3525828T (pt) 2025-01-29
US20240156977A1 (en) 2024-05-16
KR20190069493A (ko) 2019-06-19
CN110087691A (zh) 2019-08-02
AU2017344440A1 (en) 2019-05-02
AU2020260375A1 (en) 2020-11-19
MX2024003463A (es) 2024-04-03
CA3040423A1 (en) 2018-04-26
US20190269791A1 (en) 2019-09-05
CN116251196A (zh) 2023-06-13
EP4635516A2 (en) 2025-10-22
AU2024201216A1 (en) 2024-05-16
KR102338660B1 (ko) 2021-12-10
US11833216B2 (en) 2023-12-05
EP4635516A3 (en) 2026-05-06
JP7383682B2 (ja) 2023-11-20
RU2019111303A (ru) 2020-11-17
AU2020260375B2 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
US11833216B2 (en) Anti-EDB antibodies and antibody-drug conjugates
US20260139067A1 (en) Cdcp1 antibodies and antibody drug conjugates
JP6629837B2 (ja) 抗ｐｔｋ７抗体−薬物コンジュゲート
JP2024119785A (ja) 葉酸受容体アルファに特異的な抗体
WO2019018647A1 (en) ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
HK40131862A (en) Anti-edb antibodies and antibody-drug conjugates
HK40092426A (en) Anti-edb antibodies and antibody-drug conjugates
WO2025208105A1 (en) Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders
BR122024006481A2 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica e seus usos, processo para a produção de um conjugado de anticorpo-fármaco, anticorpo, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo e método para detectar domínio b extra de fibronectina
HK40012788B (en) Anti-edb antibodies and antibody-drug conjugates
BR112019007760B1 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica, ácido nucleico, vetor, processo para a produção do conjugado de anticorpofármaco e uso do conjugado de anticorpo-fármaco
HK40012788A (en) Anti-edb antibodies and antibody-drug conjugates